Notably, in mammalian cells disruption of PKC signaling impairs tumor progression and drug resistance such that PKC inhibitors have entered clinical trials for the treatment of several human cancers as single or combination therapy agents [79], [80]. This evidence concerns the gene PRRT2 and neoplasm.